Table 2.
The performance of mcfDNA sequencing versus initial blood culture and other microbiological methods reported by previous studies.
| ID | Diseases | Case/ Specimen(n) | Pathogen detection rate | Sensitivity % | Specificity % | Reference | ||
|---|---|---|---|---|---|---|---|---|
| Culture (%) | Other methods (%) | mcfDNA sequencing (%) | ||||||
| 1 | Spesis | 78 | 12.8(10/78) | - | 30.8(24/78) | 70(7/10) | 88.2(60/68) | 18 |
| 2 | Spesis | 348 | 18.1(63/348) | 37.9(169/348) a | 48.6(169/348) | 92.9(169/182) | 62.7(104/166) | 4 |
| 3 | Community-acquired pneumonia (CAP) | 15 | 6.7(1/15) | 46.7(7/15) b | 86.7(13/15) | - | - | 42 |
| 4 | Pediatric infections | 100 | 23.0(23/100) | 52.0(52/100) c | 70.0(70/100) | 91.8(56/61) | 64.1(25/39) | 102 |
| 5 | iInvasive mycobacterium | 10 | 50.0(5/10) | - | 90.0(9/10) | - | - | 53 |
| 6 | Patients with fever of unknown origin, suspected respiratory infection, sepsis, suspected endocarditis or febrile neutropenia | 82 | 19.5(16/82) | 32.9(27/82) d | 61.0(50/82) | - | - | 49 |
| 7 | Pneumonia | 18 | - | - | 66.7(12/18) | - | - | 57 |
| 8 | Pelapsed pediatric cancer patients with impending bloodstream infection (BSI) | 47 | - | - | - | 83(15/18) | 82(27/33) | 26 |
Note: Other methods are microbiological tests including: (a) cultures, serology and nucleic acid testing; (b) standard culture and PCR based methods; (c) culture, PCR, morphology, serological test, etc.; (d) blood culture, tissue bacterial culture, viral PCR, etc.